Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas
暂无分享,去创建一个
Francesco Moschella | Paolo Li Donni | Adriana Cordova | Giuseppe Cicero | Francesca Toia | M. Todaro | G. Stassi | G. Rinaldi | G. Cicero | F. Dieli | V. Orlando | Giorgio Stassi | Matilde Todaro | N. Caccamo | S. Meraviglia | P. L. Donni | F. Moschella | A. Cordova | Francesco Dieli | Nadia Caccamo | Carmela La Mendola | Valentina Orlando | Serena Meraviglia | Gaetana Rinaldi | Leonardo Zichichi | C. La Mendola | F. Toia | L. Zichichi | P. Donni
[1] G. Ogg,et al. Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes , 1998, The Journal of experimental medicine.
[2] Jeffrey Weber,et al. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). , 2008, The oncologist.
[3] Qunyuan Zhang,et al. Tumor-Infiltrating γδ T Lymphocytes Predict Clinical Outcome in Human Breast Cancer , 2012, The Journal of Immunology.
[4] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[5] J. Wiesner,et al. Microbial isoprenoid biosynthesis and human γδ T cell activation , 2003, FEBS letters.
[6] B. Bloom,et al. Natural and synthetic non-peptide antigens recognized by human γδ T cells , 1995, Nature.
[7] L. Picker,et al. HUMAN LYMPHOCYTES BEARING T CELL RECEPTOR Y / S ARE PHENOTYPICALLY DIVERSE AND EVENLY DISTRIBUTED THROUGHOUT THE LYMPHOID SYSTEM , 2022 .
[8] G. Sireci,et al. Partial and Ineffective Activation of Vγ9Vδ2 T Cells by Mycobacterium tuberculosis-Infected Dendritic Cells , 2010, The Journal of Immunology.
[9] B. Kimmel,et al. Reduced Expression of the Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by Vγ9Vδ2 T Cells1 , 2009, The Journal of Immunology.
[10] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[11] G. D. de Bock,et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.
[12] E. Oldfield,et al. Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases , 2007, Proceedings of the National Academy of Sciences.
[13] D. Kabelitz,et al. Differentiation of Resting Human Peripheral Blood γδ T Cells toward Th1- or Th2-Phenotype , 2001 .
[14] F. Poccia,et al. Differentiation of Effector/Memory Vδ2 T Cells and Migratory Routes in Lymph Nodes or Inflammatory Sites , 2003, The Journal of experimental medicine.
[15] J. Mönkkönen,et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. , 2011, Cancer research.
[16] C. Langford,et al. Distinct Cytokine-Driven Responses of Activated Blood γδ T Cells: Insights into Unconventional T Cell Pleiotropy1 , 2007, The Journal of Immunology.
[17] Natale Cascinelli,et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.
[18] Marc Bonneville,et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. , 2005, Immunity.
[19] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Bonneville,et al. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. , 1994, Science.
[21] A. Hayday. Gammadelta T cells and the lymphoid stress-surveillance response. , 2009, Immunity.
[22] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Todaro,et al. In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low‐dose interleukin‐2 for immunotherapy of advanced breast cancer patients , 2010, Clinical and experimental immunology.
[24] M. Bonneville,et al. γδ T cell effector functions: a blend of innate programming and acquired plasticity , 2010, Nature Reviews Immunology.
[25] M. Rimbert,et al. Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma , 2008, Cancer Immunology, Immunotherapy.
[26] Lisa M. Ebert,et al. Homing and Function of Human Skin γδ T Cells and NK Cells: Relevance for Tumor Surveillance , 2006, The Journal of Immunology.
[27] M. Mihm,et al. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. , 2010, American journal of clinical pathology.
[28] G. Sireci,et al. Differential activation of human γ δ cells by nonpeptide phosphoantigens , 2001, European journal of immunology.
[29] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Lambert,et al. Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy , 2011, Pigment Cell & Melanoma Research.
[31] R. Landmann,et al. Dysregulation of the host mevalonate pathway during early bacterial infection activates human TCR γδ cells , 2008, European journal of immunology.
[32] A. Hayday,et al. Identification of a Novel Proinflammatory Human Skin-Homing Vγ9Vδ2 T Cell Subset with a Potential Role in Psoriasis , 2011, The Journal of Immunology.
[33] S. Rosenberg,et al. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. , 1999, Cancer research.
[34] K. Drzewiecki,et al. Spontaneous regression of metastases from melanoma: review of the literature , 2009, Melanoma research.
[35] R. Barnhill,et al. Spontaneous regression of cutaneous tumors. , 1993, Advances in dermatology.
[36] M. Atkins,et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.
[37] C. Mackay,et al. IL‐21 enhances the potential of human γδ T cells to provide B‐cell help , 2012, European journal of immunology.
[38] P. Coulie,et al. Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? , 2011, Cancer Immunology, Immunotherapy.
[39] C. Lohse,et al. Questionable Relevance of γδ T Lymphocytes in Renal Cell Carcinoma1 , 2008, The Journal of Immunology.
[40] Yoshimasa Tanaka,et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study , 2007, Cancer Immunology, Immunotherapy.
[41] A. Ribas. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). , 2008, The oncologist.
[42] M. Todaro,et al. Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. , 2011, Blood.
[43] R. Warnke,et al. Human lymphocytes bearing T cell receptor gamma/delta are phenotypically diverse and evenly distributed throughout the lymphoid system , 1989, The Journal of experimental medicine.
[44] F. Poccia,et al. CXCR5 Identifies a Subset of Vγ9Vδ2 T Cells which Secrete IL-4 and IL-10 and Help B Cells for Antibody Production1 , 2006, The Journal of Immunology.
[45] Ceballos Pi,et al. Spontaneous regression of cutaneous tumors. , 1993 .
[46] S. Rosenberg,et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] R. Berger,et al. Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies , 2008, Clinical Cancer Research.
[48] M. Eberl,et al. A Rapid Crosstalk of Human γδ T Cells and Monocytes Drives the Acute Inflammation in Bacterial Infections , 2009, PLoS pathogens.
[49] G. De Libero,et al. Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells , 2003, The Journal of experimental medicine.
[50] H. Pehamberger,et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] A. Mackensen,et al. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.
[52] M. Eberl,et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. , 2007, Cancer research.
[53] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[54] T. Sasada,et al. Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. , 2011, Immunotherapy.